Carver Kyle 4

4 · Kadmon Holdings, Inc. · Filed Nov 9, 2021

Form 4

Period: 2021-11-09

Principal Accounting Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2021-11-09$4.84/sh−45,000$217,800→ 0 total
Exercise: $4.66Exp: 2026-12-15→ Common Stock, par value $0.001 (45,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$5.16/sh−100,000$516,000→ 0 total
Exercise: $4.34Exp: 2030-01-27→ Common Stock, par value $0.001 (100,000 underlying)
Disposition to Issuer
Common Stock
2021-11-09$9.50/sh−15,420$146,490→ 0 total
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$7.03/sh−50,000$351,500→ 0 total
Exercise: $2.47Exp: 2028-12-14→ Common Stock, par value $0.001 (50,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$5.54/sh−175,000$969,500→ 0 total
Exercise: $3.96Exp: 2031-01-08→ Common Stock, par value $0.001 (175,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2021-11-09$5.86/sh−55,000$322,300→ 0 total
Exercise: $3.64Exp: 2027-12-08→ Common Stock, par value $0.001 (55,000 underlying)

Footnotes (3)

[F1]Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
[F2]In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
[F3]Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.

Documents

1 file